SPRINGFIELD, Mo., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Paul Mueller Company (OTC: MUEL) today announced that the tender offer, announced on October 24, 2025, expired on November 21, 2025, with 31,000 shares being tendered for a total of $15,035,000. On November 25, 2025, Computershare, the Depository for the tender offer, will deliver funds to the Depository Trust Company to be disbursed to the brokerage accounts of those who tendered shares. Also, Computershare will mail checks to those registered shareholder ...

LOS ANGELES, Nov. 24, 2025 (GLOBE NEWSWIRE) -- XMax Inc., a Nevada corporation (“XMax” or the “Company”) (NASDAQ: XWIN) today announced that on November 18, 2025, it entered into a Convertible Promissory Note Purchase Agreement with Billiongold Holding Limited, pursuant to which the Company issued a convertible promissory note in the principal amount of US$5,000,000. The note matures 36 months after funding, bears interest at 6% per annum, and is convertible at the holder’s option into shares of the Company ...

Record Fiscal Year Results, with Net Income of $305.9 million, up 17% Quarterly Net Operating Revenues of $585.1 million, up 29% Record Quarterly Net Income of $85.7 million, Quarterly ROE of 15.2% Quarterly Diluted EPS of $1.57 per share, Fiscal Year of $5.89 per share NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- StoneX Group Inc. (the “Company”; NASDAQ: SNEX), a leading financial services franchise connecting clients to global markets, today announced its financial results for the fiscal fourth quarter a ...

Core Insights - iBio, Inc. will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Miami, highlighting its focus on advancing its next-generation obesity pipeline [1][2]. Company Overview - iBio is an AI-driven biotech company specializing in precision antibody therapies for cardiometabolic diseases, obesity, cancer, and other challenging conditions [4]. - The company utilizes proprietary 3D modeling and innovative drug discovery platforms to develop breakthrough antibody treatments aimed at significant unmet medical needs [4]. Key Events - Martin Brenner, CEO and Chief Scientific Officer of iBio, will engage in a fireside chat on December 4, 2025, discussing the promising non-human primate data for IBIO-610, a potential first-in-class Activin E antibody [2]. - Felipe Duran, CFO of iBio, will be available for one-on-one meetings during the conference, providing opportunities for direct engagement with investors [3]. Additional Information - A livestream of the conference will be available, and a replay will be posted on the Investor section of the iBio website [3].

Core Insights - Nanobiotix reported operational updates and financial results for Q3 2025, highlighting advancements in clinical programs and a significant financing milestone [1][3][4] Operational Highlights - The company completed a non-dilutive royalty financing transaction with HCRx valued up to $71 million, including an upfront payment of $50 million and an additional $21 million expected in one year [4][5][6] - Progress was made in the JNJ-1900 (NBTXR3) program, with the completion of the Phase 3 head and neck cancer study sponsorship transfer to Johnson & Johnson and initial data from a Phase 1 esophageal cancer study [3][4][5] - The Curadigm Nanoprimer program is emerging as a long-term growth driver, with new patent applications filed and pre-clinical data presented at industry conferences [5][6] Financial Updates - As of September 30, 2025, the company reported €20.4 million in cash and cash equivalents, with the recent financing expected to extend cash visibility into early 2028 [4][12] - The royalty financing will be repaid from a capped portion of milestones and royalties on sales of JNJ-1900, structured through a trust involving multiple parties [7] Clinical Development Outlook - Clinical updates from ongoing or completed studies of JNJ-1900 (NBTXR3) in various cancers, including melanoma, lung cancer, pancreatic cancer, and esophageal cancer, are expected in 2026 [4][8][12] - JNJ-1900 (NBTXR3) is being evaluated as a single agent and in combination therapies, with a focus on solid tumors treatable with radiotherapy [9][10][11]

Core Viewpoint - AVITA Medical, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. EST, and management will be available for one-on-one meetings with registered investors [1]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery [3]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [3]. - In the U.S., AVITA Medical holds exclusive rights to manufacture and market PermeaDerm, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3]. International Market Presence - The RECELL System is approved for promoting skin healing in various applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan (excluding RECELL GO) [4].

Core Points - Genco Shipping & Trading Limited has received a non-binding indicative proposal from Diana Shipping Inc. to acquire all outstanding shares of Genco not already owned by Diana for $20.60 per share in cash [1] - Diana Shipping currently owns approximately 14.8% of Genco's common stock [1] Company Overview - Genco Shipping & Trading Limited is a U.S.-based drybulk ship owning company focused on the global transportation of commodities, including iron ore, coal, grain, steel products, bauxite, cement, and nickel ore [5] - The company operates a fleet of 45 vessels with an average age of 12.5 years and an aggregate capacity of approximately 5,045,000 deadweight tons (dwt) [5]

Core Viewpoint - First Financial Northwest, Inc. has declared a final cash liquidation distribution of $1.30 per share as part of its Plan of Dissolution, totaling $23.30 per share distributed to shareholders [1][2]. Group 1: Cash Liquidation Distribution - The final cash liquidation distribution will be payable on December 12, 2025, to shareholders of record as of April 23, 2025 [1]. - The total cash distributions to shareholders, including the final distribution, amount to approximately $215 million [2]. Group 2: Shareholder Requirements - Shareholders holding physical stock certificates must convert them to book-entry accounts to receive their cash liquidation distributions [3]. - Georgeson LLC has been retained to assist in locating shareholders who have not responded to previous communications regarding their shares [3]. Group 3: Tax Implications - Cash liquidation distributions will be reported on Form 1099-DIV for the tax year 2025, with U.S. shareholders recognizing gain or loss based on the difference between cash received and their adjusted tax basis [4]. - Long-term capital gains for non-corporate U.S. holders are generally subject to preferential tax rates [4]. Group 4: Company Background - First Financial Northwest, Inc. is the former holding company of First Financial Northwest Bank, which was sold to Global Federal Credit Union on April 11, 2025 [6]. - The company has delisted its common stock from trading on the Nasdaq Capital Market and closed its stock transfer books effective April 21, 2025, as part of its voluntary dissolution [6].

MONTREAL, Nov. 24, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08a technology company driving innovation in advanced materials and critical process development, is pleased to announce that it has closed a non-brokered private placement of 1,883,815 common shares at a price of $0.1625 per share for gross proceeds of $306,120. The financing was completed with a European-based investment firm specializing in tailored, committed, and flexible capital solut ...

Core Insights - Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors aimed at preserving organ function [3] - The CEO, Elisabet de los Pinos, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 [1] - The company's lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and early-stage development for other ocular oncology indications and bladder cancer [3] Company Overview - Aura Biosciences is headquartered in Boston, MA, and aims to grow as an innovative global oncology company that positively transforms patients' lives [3] - The company provides a live webcast of events on its "Investors & Media" page, with replays available for 90 days [2] - Investor relations contact is Alex Dasalla, Head of Investor Relations and Corporate Communications [5]